Bayer's Two-Front Battle: A Supreme Court Verdict and a First-in-Class Drug Approval
23.06.2026 - 21:06:11 | boerse-global.de
Bayer investors are bracing for a week that could reshape the company’s trajectory on two separate fronts. The US Supreme Court is poised to rule on the Durnell case, a decision that may either contain or inflame the multibillion-dollar glyphosate and PCB liability overhang, while European and American regulators simultaneously weigh the fate of Asundexian, the experimental stroke drug meant to fill the revenue hole left by the expiring Xarelto franchise. The stock, which recently rallied nearly 8% over the past seven days to €38.70 after dipping to around €37.86, reflects the tug-of-war between optimism over the pipeline and caution over balance-sheet pressures.
The Supreme Court countdown is the more immediate trigger. Should the ruling favour Bayer, legal uncertainty would drop structurally — and the shares would likely draw a strong bid. A negative outcome, however, would aggravate what is already a punishing cash drain. The company expects legal payouts for glyphosate and PCB claims to total roughly €5 billion in 2026, a figure that helped push net financial debt back up to €32.5 billion by the end of March, after it had fallen to €29.8 billion at the close of 2025. Free cash flow is forecast to be negative this year, severely constraining any room for dividends or strategic investment.
Against this legal backdrop, management is pushing ahead with a sweeping reorganisation that aims to strip out hierarchy and cut €2 billion in administrative costs by the end of next year. The efficiency drive is necessary but not sufficient on its own: the real prize lies in the pharma pipeline, where two products are already gaining traction. Nubeqa, though embroiled in a patent dispute with Johnson & Johnson — Bayer filed an amended complaint on 15 June — and Kerendia, whose US label was expanded last year, are helping offset the Xarelto patent cliff. Xarelto revenue tumbled by a third in 2025 to $2.6 billion.
Should investors sell immediately? Or is it worth buying Bayer?
Asundexian, however, carries the heaviest weight. The oral Factor XIa inhibitor is being reviewed by the US Food and Drug Administration under Priority Review status, granted in May on the back of the pivotal OCEANIC-STROKE study. China has also awarded Priority Review, and this week the European Medicines Agency began its own assessment — the first ever European submission for a drug in this class. If all three approvals come through, Bayer would be first to market with an FXIa inhibitor, targeting a huge patient pool: stroke is the second-leading cause of death in Europe, affecting roughly 10 million people who survive with its consequences. The data shows a clear efficacy advantage in secondary prevention of ischemic stroke, with a notably low bleeding risk.
Yet even as the regulatory clock ticks, a separate threat is building from trade policy. Washington has launched an investigation under Section 301 of the Trade Act into German drug-pricing practices, accusing Berlin of artificially suppressing pharmaceutical prices. The process is already underway: the public comment period opened on 25 June, written submissions must be filed by 10 August, and a hearing is scheduled for 22 September. A worst-case outcome could see punitive tariffs on German medicines, directly hitting Bayer’s cost structure and margins. Complicating matters further, Berlin’s planned savings package for statutory health insurers is being cited by US officials as further evidence of price control — leaving Bayer squeezed from both sides of the Atlantic.
Technically, the shares are holding above the 200-day moving average of €36.33, a level that has acted as solid support during past dips. The relative strength index stands at 60.3, suggesting room to run without being overbought. But the distance to the 52-week high of €49.93 from February is still 22.5%, underscoring how much uncertainty is baked into the current price. A break below €36.33 could trigger a sharp sell-off, while a favourable Supreme Court ruling combined with steady regulatory progress might open a path back towards €40. The next major catalyst — the US trade hearing on 22 September — will test whether the positive momentum from the pipeline can outweigh the dual drag of litigation and tariff risk.
Ad
Bayer Stock: New Analysis - 23 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
